Company intelligence / Profile preview

Interactive Optics

Copenhagen, Denmark

Ownership: Private
Employees: ~80
Development stage: Other

Overview

IO102-IO103 is in phase 3 for melanoma and phase 2 for lung cancer, head & neck cancer, and melanoma; IO112 targets Arginase 1 in phase 2 for multiple cancers; IO170 is in development for solid tumors.[1][6]

Therapeutic areas: Oncology
Modalities: Vaccine
Industry: Biotech

Beyond the preview

Go deeper on Interactive Optics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interactive Optics.

Explore the full profile